{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:54:04Z","timestamp":1791154444620,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"DBT-New Delhi","award":["DBT-JRF 2009-10\/515"],"award-info":[{"award-number":["DBT-JRF 2009-10\/515"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.gene.2014.11.022","type":"journal-article","created":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T10:02:35Z","timestamp":1415786555000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Huntington's disease: An update of therapeutic strategies"],"prefix":"10.1016","volume":"556","author":[{"given":"Ashok","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Kumar","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9246","key":"10.1016\/j.gene.2014.11.022_bb0005","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","article-title":"Motor and cognitive improvements in patients with Huntington's disease after neural, transplantation","volume":"356","author":"Bachoud-L\u00e9vi","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gene.2014.11.022_bb0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","article-title":"Effect of fetal neural transplants in patients with Huntington's disease 6years after surgery: a long-term follow-up study","volume":"5","author":"Bachoud-L\u00e9vi","year":"2006","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.gene.2014.11.022_bb0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/nbdi.1998.0168","article-title":"Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length","volume":"4","author":"Becher","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.gene.2014.11.022_bb0020","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bbrc.2004.08.035","article-title":"Deranged neuronal calcium signalling and Huntington disease","volume":"322","author":"Bezprozvanny","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.gene.2014.11.022_bb0025","doi-asserted-by":"crossref","first-page":"17187","DOI":"10.1074\/jbc.M501250200","article-title":"Mechanism of human SIRT1 activation by resveratrol","volume":"280","author":"Borra","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gene.2014.11.022_bb0030","first-page":"1353","article-title":"Clinical experience with risperidone and memantine in the treatment of Huntington's disease","volume":"98","author":"Cankurtaran","year":"2006","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.gene.2014.11.022_bb0035","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.neurobiolaging.2004.11.008","article-title":"Somatic mitochondrial DNA mutations in single neurons and glia","volume":"26","author":"Cantuti-Castelvetri","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.gene.2014.11.022_bb0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/1097-0282(2000)56:2<85::AID-BIP1054>3.0.CO;2-7","article-title":"Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), mithramycin: roles of minor groove width and ligand flexibility","volume":"56","author":"Chakrabarti","year":"2000","journal-title":"Biopolymers"},{"key":"10.1016\/j.gene.2014.11.022_bb0045","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/80538","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2014.11.022_bb0050","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","article-title":"Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release","volume":"13","author":"Choo","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.gene.2014.11.022_bb0055","doi-asserted-by":"crossref","first-page":"16685","DOI":"10.1073\/pnas.0707842104","article-title":"A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2\u20138 in the R6\/2 transgenic mouse","volume":"104","author":"Chopra","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2014.11.022_bb0060","series-title":"Kumar and Clark Clinical Medicine","first-page":"1173","article-title":"Neurological disease","author":"Clarke","year":"2005"},{"key":"10.1016\/j.gene.2014.11.022_bb0065","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuritis in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.gene.2014.11.022_bb0070","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","article-title":"Green tea (\u2212)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models","volume":"15","author":"Ehrnhoefer","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.gene.2014.11.022_bb0075","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.gene.2014.11.022_bb0080","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.gene.2014.11.022_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/exnr.1993.1008","article-title":"Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection","volume":"119","author":"Filloux","year":"1993","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.gene.2014.11.022_bb0090","series-title":"Principles of Medical Genetics","author":"Gelehrter","year":"1998"},{"key":"10.1016\/j.gene.2014.11.022_bb0095","series-title":"Textbook of Biochemistry: With Clinical Correlations","first-page":"209","article-title":"Protein synthesis: translation and posttranslational modifications","author":"Glitz","year":"2011"},{"key":"10.1016\/j.gene.2014.11.022_bb0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.gene.2014.11.022_bb0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/bj20021234","article-title":"Transglutaminases: nature's biological glues","volume":"368","author":"Griffin","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.gene.2014.11.022_bb0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0306-4522(97)00192-9","article-title":"Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats","volume":"81","author":"Guyot","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.gene.2014.11.022_bb0115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/CS20050148","article-title":"Pharmaceutical, cellular and genetic therapies for Huntington's disease","volume":"110","author":"Handley","year":"2006","journal-title":"Clin. Sci."},{"key":"10.1016\/j.gene.2014.11.022_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/CS20050148","article-title":"Pharmaceutical, cellular and genetic therapies for Huntington's disease","volume":"110","author":"Handley","year":"2006","journal-title":"Clin. Sci."},{"key":"10.1016\/j.gene.2014.11.022_bb0125","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2014.11.022_bb0130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ana.21891","article-title":"Minocycline is protective in a mouse model of Huntington's disease","volume":"54","author":"Hersch","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.gene.2014.11.022_bb0135","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, and bioavailable in brain and reduces serum 8OH2'dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.gene.2014.11.022_bb0140","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2014.11.022_bb0145","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1212\/WNL.45.10.1879","article-title":"Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients","volume":"45","author":"Horton","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.gene.2014.11.022_bb0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","article-title":"Allele-selective inhibition of mutant huntingtin by peptide nucleic acid\u2013peptide conjugates, locked nucleic acid, and small interfering RNA","volume":"1175","author":"Hu","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.gene.2014.11.022_bb0155","doi-asserted-by":"crossref","first-page":"40282","DOI":"10.1074\/jbc.M508786200","article-title":"HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin","volume":"280","author":"Iwata","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gene.2014.11.022_bb0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0166-2236(00)01568-X","article-title":"Neuronal cell death in Huntington's disease: a potential role for dopamine","volume":"23","author":"Jakel","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.gene.2014.11.022_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.gene.2014.11.022_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0197-0186(01)00060-2","article-title":"Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications","volume":"40","author":"Karpuj","year":"2002","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.gene.2014.11.022_bb0175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.870110310","article-title":"A controlled trial of remacemide hydrochloride in Huntington's disease","volume":"11","author":"Kieburtz","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.gene.2014.11.022_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature00900","article-title":"Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease","volume":"418","author":"Kim","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.gene.2014.11.022_bb0185","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats","volume":"330","author":"Kremer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2014.11.022_bb0190","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.53.5.1000","article-title":"Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial","volume":"53","author":"Kremer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.gene.2014.11.022_bb0195","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.brainres.2006.08.035","article-title":"Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease","volume":"1118","author":"Lee","year":"2006","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.gene.2014.11.022_bb0200","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.spen.2006.11.006","article-title":"Trinucleotide repeat disorders","volume":"14","author":"Lutz","year":"2007","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.gene.2014.11.022_bb0205","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1460-9568.2006.04686.x","article-title":"Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells","volume":"23","author":"Mao","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.gene.2014.11.022_bb0210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0304-3940(95)12137-S","article-title":"Effect of riluzole on quinolinate induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission","volume":"201","author":"Mary","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.gene.2014.11.022_bb0215","series-title":"Emery's Elements of Medical Genetics","author":"Mueller","year":"2001"},{"issue":"5","key":"10.1016\/j.gene.2014.11.022_bb0220","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioural and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.gene.2014.11.022_bb0225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mcne.2000.0872","article-title":"Inhibition of Huntington synthesis by antisense oligodeoxynucleotides","volume":"16","author":"Nellemann","year":"2000","journal-title":"Mol. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.gene.2014.11.022_bb0230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1176\/jnp.15.1.108","article-title":"Neurodegenerative disorders: George Huntington's description of hereditary chorea","volume":"15","author":"Neylan","year":"2003","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.gene.2014.11.022_bb0235","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1523\/JNEUROSCI.0106-08.2008","article-title":"NH2-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking","volume":"28","author":"Orr","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.gene.2014.11.022_bb0240","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/exnr.1997.6520","article-title":"Hantraye P. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration","volume":"146","author":"Palfi","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.gene.2014.11.022_bb0245","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM197302152880703","article-title":"Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain","volume":"288","author":"Perry","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2014.11.022_bb0250","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.expneurol.2005.07.021","article-title":"Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease","volume":"196","author":"Raamsdonk","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.gene.2014.11.022_bb0255","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.gene.2014.11.022_bb0260","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/74447","article-title":"Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro","volume":"18","author":"Reubinoff","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.gene.2014.11.022_bb0265","doi-asserted-by":"crossref","first-page":"19176","DOI":"10.1073\/pnas.0606373103","article-title":"ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease","volume":"103","author":"Ryu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2014.11.022_bb0270","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"Sanchez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.gene.2014.11.022_bb0275","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1074\/jbc.M609532200","article-title":"A novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein","volume":"282","author":"Sarkar","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gene.2014.11.022_bb0280","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/hmg\/ddm294","article-title":"A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin","volume":"17","author":"Sarkar","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.gene.2014.11.022_bb0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.gene.2014.11.022_bb0290","doi-asserted-by":"crossref","first-page":"13726","DOI":"10.1073\/pnas.95.23.13726","article-title":"Derivation of pluripotent stem cells from cultured human primordial germ cells","volume":"95","author":"Shamblott","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2014.11.022_bb0295","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.gene.2014.11.022_bb0300","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/brain\/103.1.179","article-title":"Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue","volume":"103","author":"Spokes","year":"1980","journal-title":"Brain"},{"key":"10.1016\/j.gene.2014.11.022_bb0305","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","article-title":"Modulation of nucleosome dynamics in Huntington's disease","volume":"16","author":"Stack","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.gene.2014.11.022_bb0310","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","article-title":"Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease","volume":"10","author":"Tanaka","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2014.11.022_bb0315","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","article-title":"Dopaminergic signalling and striatal neurodegeneration in Huntington's disease","volume":"27","author":"Tang","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.gene.2014.11.022_bb0320","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"The HDCRG","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.gene.2014.11.022_bb0325","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2014.11.022_bb0330","series-title":"Emery's Elements of Medical Genetics","author":"Turnpenny","year":"2007"},{"key":"10.1016\/j.gene.2014.11.022_bb0335","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nchembio852","article-title":"Selective inhibitors of death in mutant huntingtin cells","volume":"3","author":"Varma","year":"2007","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"10.1016\/j.gene.2014.11.022_bb0340","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/mds.20197","article-title":"Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis","volume":"19","author":"Verme","year":"2004","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.gene.2014.11.022_bb0345","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/hmg\/ddq464","article-title":"Mootha Meclizine is neuroprotective in models of Huntington's disease","volume":"20","author":"Vishal","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.gene.2014.11.022_bb0350","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/hmg\/ddl017","article-title":"Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin","volume":"15","author":"Wang","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.gene.2014.11.022_bb0355","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(02)00835-8","article-title":"Directed differentiation of embryonic stem cells into motor neurons","volume":"110","author":"Wichterle","year":"2002","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.gene.2014.11.022_bb0360","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases","volume":"109","author":"Lichuan","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.gene.2014.11.022_bb0365","series-title":"Medical Genetics","author":"Young","year":"2005"},{"key":"10.1016\/j.gene.2014.11.022_bb0370","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","article-title":"Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease","volume":"33","author":"Zeron","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.gene.2014.11.022_bb0375","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nbt1201-1129","article-title":"In vitro differentiation of transplantable neural precursors from human embryonic stem cells","volume":"19","author":"Zhang","year":"2001","journal-title":"Nat. Biotechnol."},{"issue":"5529","key":"10.1016\/j.gene.2014.11.022_bb0380","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111914012839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111914012839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T08:13:51Z","timestamp":1566029631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111914012839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0378111914012839"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2014.11.022","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Huntington's disease: An update of therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2014.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}